VIDEO: Daratumumab maintenance shows clinical benefit in multiple myeloma
Click Here to Manage Email Alerts
Daratumumab maintenance demonstrated clinical benefit in transplant-eligible patients with newly diagnosed multiple myeloma, according to phase 3 data presented at the virtual ASCO Annual Meeting.
“If you had [daratumumab] as part of your induction, it didn’t seem to give you the same benefit to continue to use it as maintenance; but, if you didn’t get [daratumumab] as induction, then you clearly showed benefit having it in the maintenance,” Amrita Y. Krishnan, MD, FACP, director of Judy and Bernard Briskin Multiple Myeloma Center and professor of hematology/hematopoietic cell transplantation at City of Hope Cancer Center, told Healio in a video interview.
Collapse
Moreau P, et al. Abstract 8004. Presented at: ASCO Annual Meeting (virtual); June 4-8, 2021.
Read more about
Click Here to Manage Email Alerts